

Index

A

AAD, 165
ABCDE system, 83, 84
Activation, 122
Adjuvant radiotherapy, 106, 107
Advanced melanoma, 127
Age, 10, 33
Age-standardized rate, 5, 6, 7
Albinism, 33
Anatomic distribution, 12
Antigen presenting cell, 122
Attenuative type, 67

B

BAD, 166
Basic science, 121
Biology, 123
Biomarkers, 39, 130
Biopsy, 84, 93
Body sites, 28
BRCA2 mutation, 81

C

CDKN2A, 81
Chemotherapy, 147
Chest X-ray, 169
Clark's levels, 85
Cleft formation, 68
Clinical application, 121
Clinical presentation, 79
Clinical, 82
Clinically negative, 93

Concomitant agents, 109
Computed tomography, 171
Congenital melanocytic nevi, 81
Consumption of epidermis, 68
CTLA-4, 123, 124
Cyclooxygenase-2, 45

D

Detection, 145
Diagnosis, 34, 82
Diagnostic strategies, 84
Disease types, 85

E

Elective lymph node dissection, 95
ELND, 95
Embryonic phenotype, 60
Endogenous enzyme inhibitors, 47
Enzyme markers, 47
Enzymes, 42
Epidemiology, 3, 23
Epidermal hyperplasia, 69
Epidermal involvement, 70
Epidermis, 68
ESMO, 165
Ethnicity, 5
Etiology, 80

F

FAMMM, 81
Fitzpatrick classification, 83

G

Genetics, 33
 Geography, 5, 24
 GMMANZ, 167
 Guidelines for excision, 92
 Guidelines, 165

H

Heterogeneity, 57
 Heterogeneous, 59, 71
 Histologic confirmation, 84
 Historical perspective, 102
 HIV, 32

I

Imaging, 169
 Immune checkpoint inhibitors, 121
 In transit metastatic disease, 97
 Incidence, 5, 26
 Increased risk, 81
 Indications, 94
 Infiltrative type, 67
 Ipilimumab, 127

L

Laboratory tests, 168
 Lactate dehydrogenase, 43
 Lentigo maligna, 104
 Liposomes, 148
 Localized disease, 92
 Long-term management, 161
 Lymph node ultrasonography, 170
 Lymphadenectomy, 95, 96

M

Magnetic resonance imaging, 171
 Malignant melanoma, 39

Management, 161
 Margins for surgical excision, 93
 Matrix metalloproteinases, 46
 Melanocytes, 4, 80
 Melanoma, 3, 23, 39, 57, 67, 79, 91, 101, 121, 143
 Metabolites, 43
 Metastatic melanoma, 97
 MOHS micrographic surgery, 92
 Mortality, 13, 34
 Mucosal melanomas, 104

N

Nevi, 31
 Nano therapies, 147
 Nanohydrogels, 148
 Nanomedicine, 143
 NCCN, 165
 Ninosomes, 148
 Nivolumab, 131
 Nodal 61, 107
 Nonprotein biomarkers, 50
 Nucleic acids, 43

O

Ocular melanomas, 105

P

Palliative radiotherapy, 107
 Patient history, 82
 PD-1, 126, 128, 131
 Pembrolizumab, 131
 Physical examination, 83
 Plasticity, 57
 Polymeric nanoparticles, 147
 Population, 26, 81
 Positron emission tomography, 171

Predictions, 12
Prevention, 14
Primary prevention, 15
Progenitor markers, 43, 49
Prognostic factors, 85
Prognostic impact, 67, 72
Proliferation, 68

R

Radiation therapy, 101
Radiotherapy, 147
Reactive hyperplasia, 67, 69
Recommendations, 82
Re-epithelialization, 67, 69
Regional lymph nodes, 93
Resistance, 133
Resolved ulceration, 69
Risk factors, 29, 80

S

S100 proteins, 43, 48
SBRT, 101, 103
Screening, 80, 82
Secondary prevention, 15
Secreted proteins, 42
Sentinel lymph node biopsy, 93
Sentinel node, 94
Sex, 10, 32
Short-term management, 161
SLNB, 93, 94
South Africa, 23, 24
SRS, 101, 103
Stage, 34
Staging, 86, 87
Stem cell markers, 43, 49
Stem cell, 62
Stereotactic body radiotherapy, 101, 103

Stereotactic radiosurgery, 101, 103
Subtypes, 85
Sun exposure, 31
Surgical consideration, 96
Surgical management, 91
Surveillance, 162
Swiss guidelines, 167

T

TCE, 162
T-cell responses, 122
TCP, 167
Theranostic nanomedicine, 148
Total cutaneous examination, 162
Total cutaneous photography, 167
Toxicity, 125, 129
Trauma, 31
Treatment, 121, 145
Trends, 12
Tyrosinase, 44

U

Ulcerated melanoma, 67
Ulceration, 68
Ultraviolet, 5

V

Vascular phenotype, 58

W

Weather, 25

X

Xeroderma pigmentosum, 81